Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD

6.31  -1.54 (-19.62%)

Premarket: 6.51 +0.2 (+3.17%)

Fundamental Rating

2

RCKT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. RCKT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RCKT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.
In the past year RCKT has reported a negative cash flow from operations.
RCKT had negative earnings in each of the past 5 years.
RCKT had a negative operating cash flow in each of the past 5 years.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RCKT has a Return On Assets of -49.03%. This is comparable to the rest of the industry: RCKT outperforms 46.89% of its industry peers.
The Return On Equity of RCKT (-55.86%) is better than 61.63% of its industry peers.
Industry RankSector Rank
ROA -49.03%
ROE -55.86%
ROIC N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

RCKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

RCKT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RCKT has more shares outstanding
Compared to 1 year ago, RCKT has a worse debt to assets ratio.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

RCKT has an Altman-Z score of 2.09. This is not the best score and indicates that RCKT is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of RCKT (2.09) is better than 73.71% of its industry peers.
RCKT has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RCKT (0.04) is worse than 61.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 2.09
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 9.30 indicates that RCKT has no problem at all paying its short term obligations.
RCKT has a better Current ratio (9.30) than 77.09% of its industry peers.
A Quick Ratio of 9.30 indicates that RCKT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.30, RCKT is in the better half of the industry, outperforming 77.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.3
Quick Ratio 9.3
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.14% over the past year.
EPS 1Y (TTM)7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RCKT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.51% yearly.
The Revenue is expected to grow by 687.06% on average over the next years. This is a very strong growth
EPS Next Y11.42%
EPS Next 2Y17.96%
EPS Next 3Y27.01%
EPS Next 5Y21.51%
Revenue Next Year182791%
Revenue Next 2Y7249.53%
Revenue Next 3Y2418.84%
Revenue Next 5Y687.06%

3.3 Evolution

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as RCKT's earnings are expected to grow with 27.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.96%
EPS Next 3Y27.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCKT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (5/6/2025, 8:00:02 PM)

Premarket: 6.51 +0.2 (+3.17%)

6.31

-1.54 (-19.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners104.13%
Inst Owner Change0.46%
Ins Owners3.11%
Ins Owner Change19.87%
Market Cap672.84M
Analysts84.17
Price Target40.39 (540.1%)
Short Float %13.14%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.88%
Min EPS beat(2)8.41%
Max EPS beat(2)15.34%
EPS beat(4)3
Avg EPS beat(4)6.89%
Min EPS beat(4)-1.16%
Max EPS beat(4)15.34%
EPS beat(8)6
Avg EPS beat(8)8.87%
EPS beat(12)7
Avg EPS beat(12)3.23%
EPS beat(16)10
Avg EPS beat(16)2.92%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.29%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)12.17%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-6.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)-2.73
EYN/A
EPS(NY)-2.42
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.97
OCFYN/A
SpS0
BVpS4.34
TBVpS3.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.03%
ROE -55.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.3
Quick Ratio 9.3
Altman-Z 2.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)144.02%
Cap/Depr(5y)620.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.13%
EPS Next Y11.42%
EPS Next 2Y17.96%
EPS Next 3Y27.01%
EPS Next 5Y21.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year182791%
Revenue Next 2Y7249.53%
Revenue Next 3Y2418.84%
Revenue Next 5Y687.06%
EBIT growth 1Y-5.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.52%
EBIT Next 3Y29.67%
EBIT Next 5YN/A
FCF growth 1Y-1.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.6%
OCF growth 3YN/A
OCF growth 5YN/A